Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stephen Miller
Northwestern University at Chicago, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cour Pharmaceutical Development Company, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This project touches intellectual property co-developed by Miller that has been licensed to Cour Pharmaceuticals, a company he co-founded and has equity interests in. Cour’s platform involves nanoparticles that are coated with a proprietary surface polymer (PLGA) and loaded with antigens that induce immune system tolerance to that specific antigen. This research proposes that treatment with PLG nanoparticles can improve seizure outcomes in our two-hit model of epileptogenesis. The approaches that target inflammation and restrict brain infiltration by inflammatory leukocyte subsets in the absence of the complicating effects of steroids are highly novel and may be a major step forward for the translation of novel treatments for the root cause of epilepsy. The close intersection of Cour interests and this research activity result in a perceived conflict of interest that should be managed.
Novel Therapies for Epilepsy Using Biodegradable Immune-Modifying Nanoparticles
The proposed studies are designed to determine the role of blood-derived inflammatory monocytes/macrophages in mediating CNS damage in a two-hit model of status epilepticus (SE) and the mechanism(s) by which early therapy with biodegradable carboxylated monocyte-targeting PLG nanoparticles (IMPs) and regulatory T cells can be employed to limit neuropathology in SE. This work should provide critical pre-clinical information relevant to the translation and clinical testing of the IMP platform for the treatment of SE.
Filed on August 31, 2015.
Tell us what you know about Stephen Miller's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Stephen Miller filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Stephen Miller | Northwestern University at Chicago | Conflict of Interest | Cour Pharmaceutical Development Company, Inc. | $20,000 - $39,999 |
| Stephen Miller | Northwestern University at Chicago | Conflict of Interest | Cour Pharmaceutical Development Company, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.